-
AP-1 Inhibition Induces Ferroptosis in Multiple Myeloma via
2026-07-04
This study reveals that T-5224, a selective C-Fos/AP-1 inhibitor, triggers ferroptotic cell death in multiple myeloma by downregulating PI3K/AKT signaling and key ferroptosis regulators. These findings expand the mechanistic understanding of T-5224 in myeloma beyond apoptosis, highlighting ferroptosis as a relevant therapeutic vulnerability.
-
Grazoprevir Hydrate: Translational Impact on Challenging HCV
2026-07-03
Explore how Grazoprevir hydrate, a next-generation HCV NS3/4A protease inhibitor, revolutionizes hepatitis C virus replication inhibition—especially in complex clinical settings like HIV/HCV coinfection and chronic kidney disease. This article provides a unique, evidence-driven perspective and actionable guidance distinct from workflow-focused reviews.
-
Clarithromycin as a CYP3A Inhibitor: Optimizing Drug-Drug In
2026-07-03
Clarithromycin’s potent CYP3A inhibition makes it an indispensable tool for drug-drug interaction and pharmacokinetic studies, especially in the context of statin and cardiovascular agent metabolism. This guide delivers actionable workflows, troubleshooting insights, and the latest reference-driven protocol enhancements for maximizing data integrity and reproducibility.
-
Catalpol Reduces Depression via NLRP3 Inflammasome Modulatio
2026-07-02
This study demonstrates that Catalpol alleviates depressive-like behaviors in CUMS mice by modulating oxidative stress and inhibiting the NLRP3 inflammasome pathway. These mechanistic insights highlight Catalpol’s translational potential for neuroprotection research targeting neuroinflammatory processes.
-
NMDA in Translational Neuroscience: Precision Tools for Exci
2026-07-02
This thought-leadership article for translational researchers explores how NMDA (N-Methyl-D-aspartic acid) enables precise modeling of excitotoxicity and ferroptosis in neurodegenerative disease research. Drawing on recent glaucoma studies and competitive benchmarking, it delivers mechanistic insight, protocol guidance, and a strategic vision for future applications. The discussion bridges molecular understanding with workflow optimization, highlighting how APExBIO’s NMDA empowers data-driven discovery beyond standard reagent use.
-
PA-824: Bicyclic Nitroimidazole Derivative in TB Workflows
2026-07-01
PA-824 empowers tuberculosis research with dual action against drug-sensitive and drug-resistant Mycobacterium tuberculosis. Learn how to optimize protocols, troubleshoot challenges, and harness the latest combination therapy insights for next-generation TB assay success.
-
T-5224: Advanced Modulation of Neuroinflammation and Mechano
2026-07-01
Explore the unique capabilities of T-5224, a selective C-Fos/AP-1 inhibitor, in dissecting neuroinflammatory pathways and mechanosensory hypersensitivity. This article delivers new insights into its application for advanced inflammation research, beyond conventional arthritis models.
-
HOXC8 Suppresses Pyroptosis in NSCLC via Caspase-1 Regulatio
2026-06-30
This study establishes that HOXC8 inhibits pyroptotic cell death in non-small cell lung carcinoma (NSCLC) by repressing caspase-1 expression through HDAC1/2 recruitment. These findings clarify the molecular interplay between HOXC8, inflammatory caspase signaling, and tumorigenesis, providing new mechanistic context for inflammation research.
-
Cell Senescence β-Galactosidase Staining Kit: Reliable SA-β-
2026-06-30
The Cell Senescence β-Galactosidase Staining Kit enables artifact-free, highly specific detection of senescence-associated β-galactosidase (SA-β-Gal) activity in cells and tissues. This SA-β-Gal staining kit is optimized for selectivity, workflow compatibility, and robust performance in cellular senescence assays.
-
Naftifine HCl: Optimizing Applied Antifungal Research Workfl
2026-06-29
Naftifine HCl empowers researchers to dissect fungal membrane biosynthesis and evaluate topical antifungal strategies in high-fidelity experimental systems. This article translates bench-validated workflows, protocol parameters, and key troubleshooting tactics into actionable guidance, revealing how APExBIO’s high-purity allylamine antifungal agent accelerates scientific discovery.
-
MOTS-c Suppresses Oxeiptosis to Protect Neonatal Hearts in H
2026-06-29
This study demonstrates that the mitochondrial peptide MOTS-c mitigates hyperoxia-induced cardiac injury in neonatal mice by inhibiting oxeiptosis through stabilization of the KEAP1-PGAM5 interaction. These findings highlight a novel mechanism of ROS-specific cell death regulation with relevance for therapeutic strategies in neonatal cardiac care.
-
Quercetin Inhibits Ferroptosis and Protects Liver in Wilson’
2026-06-28
This study demonstrates that quercetin alleviates liver injury in Wilson’s disease by directly inhibiting ferroptosis, particularly via suppression of the ACSL4/LPCAT3/ALOX15 pathway. These findings offer mechanistic insight into quercetin’s anti-ferroptotic action and suggest practical targets for the treatment of metal toxicity–related liver disorders.
-
Patient-Derived Gastric Cancer Assembloids Model Tumor-Strom
2026-06-27
This study introduces patient-derived gastric cancer assembloids that integrate matched tumor organoids and autologous stromal cell subpopulations, offering a physiologically relevant platform for drug response analysis and resistance mechanism discovery. The model enables more predictive preclinical testing, advancing personalized oncology research.
-
Targeting NUAK1/2 to Reduce Pathological Tau in Alzheimer’s
2026-06-26
Taylor et al. (2023) provide the first direct evidence that tau phosphorylated at serine 356 (p-tau Ser356) is closely associated with Alzheimer’s pathology in human brain tissue, and that selective NUAK1/2 inhibition by WZ4003 can lower this tau species ex vivo. These findings offer mechanistic insight into kinase-driven tau accumulation and highlight translational opportunities for therapeutic development in neurodegeneration.
-
Sulfaphenazole: Potent CYP2C9 Inhibitor for Vascular Researc
2026-06-26
Sulfaphenazole is a selective CYP2C9 inhibitor with proven efficacy in vascular endothelial function research and antibacterial applications. Peer-reviewed studies confirm its ability to restore endothelium-dependent vasodilation and reduce oxidative stress in diabetic animal models. The compound supports precise modulation of drug metabolism and offers a favorable safety profile for laboratory workflows.